The development and validation of a medicines optimisation tool to protect the physical health of people with severe mental illness (OPTIMISE).
Medicines Optimisation
Mental Illness
Physical Health
Screening Tool
Severe Mental Illness
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
03 09 2022
03 09 2022
Historique:
received:
16
12
2021
accepted:
29
08
2022
entrez:
3
9
2022
pubmed:
4
9
2022
medline:
9
9
2022
Statut:
epublish
Résumé
The life expectancy of people with severe mental illness (SMI) is shorter than those without SMI, with multimorbidity and poorer physical health contributing to health inequality. Screening tools could potentially assist the optimisation of medicines to protect the physical health of people with SMI. The aim of our research was to design and validate a medicines optimisation tool (OPTIMISE) to help clinicians to optimise physical health in people with SMI. A review of existing published guidelines, PubMed and Medline was carried out. Literature was examined for medicines optimisation recommendations and also for reference to the management of physical illness in people with mental illness. Potential indicators were grouped according to physiological system. A multidisciplinary team with expertise in mental health and the development of screening tools agreed that 83 indicators should be included in the first draft of OPTIMISE. The Delphi consensus technique was used to develop and validate the contents. A 17-member multidisciplinary panel of experts from the UK and Ireland completed 2 rounds of Delphi consensus, rating their level of agreement to 83 prescribing indicators using a 5-point Likert scale. Indicators were accepted for inclusion in the OPTIMISE tool after achieving a median score of 1 or 2, where 1 indicated strongly agree and 2 indicated agree, and 75 Consensus was achieved after 2 rounds of Delphi for 62 prescribing indicators where 53 indicators were accepted after round 1 and a further 9 indicators were accepted after round 2. Interrater reliability of OPTIMISE between physicians and pharmacists indicated a substantial level of agreement with a kappa statistic of 0.75. OPTIMISE is a 62 indicator medicines optimisation tool designed to assist decision making in those treating adults with SMI. It was developed using a Delphi consensus methodology and interrater reliability is substantial. OPTIMISE has the potential to improve medicines optimisation by ensuring preventative medicines are considered when clinically indicated. Further research involving the implementation of OPTIMISE is required to demonstrate its true benefit. This article does not report the results of a health care intervention on human participants.
Sections du résumé
BACKGROUND
The life expectancy of people with severe mental illness (SMI) is shorter than those without SMI, with multimorbidity and poorer physical health contributing to health inequality. Screening tools could potentially assist the optimisation of medicines to protect the physical health of people with SMI. The aim of our research was to design and validate a medicines optimisation tool (OPTIMISE) to help clinicians to optimise physical health in people with SMI.
METHODS
A review of existing published guidelines, PubMed and Medline was carried out. Literature was examined for medicines optimisation recommendations and also for reference to the management of physical illness in people with mental illness. Potential indicators were grouped according to physiological system. A multidisciplinary team with expertise in mental health and the development of screening tools agreed that 83 indicators should be included in the first draft of OPTIMISE. The Delphi consensus technique was used to develop and validate the contents. A 17-member multidisciplinary panel of experts from the UK and Ireland completed 2 rounds of Delphi consensus, rating their level of agreement to 83 prescribing indicators using a 5-point Likert scale. Indicators were accepted for inclusion in the OPTIMISE tool after achieving a median score of 1 or 2, where 1 indicated strongly agree and 2 indicated agree, and 75
RESULTS
Consensus was achieved after 2 rounds of Delphi for 62 prescribing indicators where 53 indicators were accepted after round 1 and a further 9 indicators were accepted after round 2. Interrater reliability of OPTIMISE between physicians and pharmacists indicated a substantial level of agreement with a kappa statistic of 0.75.
CONCLUSIONS
OPTIMISE is a 62 indicator medicines optimisation tool designed to assist decision making in those treating adults with SMI. It was developed using a Delphi consensus methodology and interrater reliability is substantial. OPTIMISE has the potential to improve medicines optimisation by ensuring preventative medicines are considered when clinically indicated. Further research involving the implementation of OPTIMISE is required to demonstrate its true benefit.
TRIAL REGISTRATION
This article does not report the results of a health care intervention on human participants.
Identifiants
pubmed: 36057589
doi: 10.1186/s12888-022-04235-0
pii: 10.1186/s12888-022-04235-0
pmc: PMC9441032
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
585Informations de copyright
© 2022. The Author(s).
Références
BMC Geriatr. 2019 Feb 13;19(1):40
pubmed: 30760204
Lancet. 2012 Jul 7;380(9836):37-43
pubmed: 22579043
BMJ. 2017 May 23;357:j2099
pubmed: 28536104
Patient Prefer Adherence. 2017 Mar 03;11:449-468
pubmed: 28424542
Ther Adv Psychopharmacol. 2020 Sep 25;10:2045125320957119
pubmed: 33029344
Schizophr Bull. 2013 Mar;39(2):295-305
pubmed: 22927670
JAMA Psychiatry. 2015 Apr;72(4):334-41
pubmed: 25671328
Ann Pharmacother. 2009 Jul;43(7):1239-44
pubmed: 19584381
Lancet. 2012 Apr 7;379(9823):1310-9
pubmed: 22357106
World Psychiatry. 2011 Jun;10(2):138-51
pubmed: 21633691
Int J Clin Pharm. 2018 Jun;40(3):543-549
pubmed: 29704184
World Psychiatry. 2011 Feb;10(1):52-77
pubmed: 21379357
J Clin Pharm Ther. 2013 Oct;38(5):360-72
pubmed: 23550814
J Psychosom Res. 2018 Dec;115:24-31
pubmed: 30470313
J Am Geriatr Soc. 2015 Nov;63(11):2227-46
pubmed: 26446832
Age Ageing. 2013 Jan;42(1):116-20
pubmed: 22832380
BMJ. 2013 May 21;346:f2539
pubmed: 23694688
J Psychopharmacol. 2010 Nov;24(4 Suppl):61-8
pubmed: 20923921
BMJ Open. 2014 Oct 01;4(9):e006084
pubmed: 25273813
Lancet Public Health. 2019 Nov;4(11):e583-e591
pubmed: 31677777
Aust N Z J Psychiatry. 2012 Aug;46(8):735-52
pubmed: 22696547
Age Ageing. 2015 Mar;44(2):213-8
pubmed: 25324330
Drug Saf. 2017 Oct;40(10):871-886
pubmed: 28776179
J Health Psychol. 2016 Feb;21(2):138-51
pubmed: 24713156
Br J Clin Pharmacol. 2021 Jan;87(1):189-209
pubmed: 32436288
Psychol Med. 2017 Oct;47(13):2217-2228
pubmed: 28397632
Soc Psychiatry Psychiatr Epidemiol. 2014 May;49(5):673-82
pubmed: 24562320
Lancet Psychiatry. 2019 May;6(5):379-390
pubmed: 30975539
BMJ Open. 2016 Sep 06;6(9):e012079
pubmed: 27601499
BMJ Open. 2017 Jan 6;7(1):e013881
pubmed: 28062471
Expert Rev Clin Pharmacol. 2020 Jan;13(1):15-22
pubmed: 31790317
PLoS One. 2019 Sep 18;14(9):e0221521
pubmed: 31532772
Age Ageing. 2017 Jul 1;46(4):600-607
pubmed: 28119312
PLoS One. 2019 May 24;14(5):e0217406
pubmed: 31125358
BMJ Open. 2015 Dec 15;5(12):e009010
pubmed: 26671955
Eur Psychiatry. 2011 Apr;26(3):144-58
pubmed: 21295450
PLoS Med. 2020 Oct 13;17(10):e1003286
pubmed: 33048923
Br J Psychiatry. 2016 Apr;208(4):322-9
pubmed: 26941263
Int J Clin Pharmacol Ther. 2008 Feb;46(2):72-83
pubmed: 18218287
Eur J Clin Pharmacol. 2018 Mar;74(3):331-338
pubmed: 29159488
Arch Gen Psychiatry. 2009 Jul;66(7):713-20
pubmed: 19581562
Age Ageing. 2009 Sep;38(5):603-6
pubmed: 19435757
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
Pharmacopsychiatry. 2011 Jul;44(5):183-8
pubmed: 21739416
BMC Health Serv Res. 2014 Oct 30;14:484
pubmed: 25410615
J Ment Health. 2018 Aug;27(4):322-328
pubmed: 28857636
BMJ Open. 2019 Jun 3;9(6):e026769
pubmed: 31164366
J Psychopharmacol. 2016 Aug;30(8):717-48
pubmed: 27147592
Drug Saf. 2014 Feb;37(2):79-90
pubmed: 24403009
Atherosclerosis. 2019 Nov;290:140-205
pubmed: 31591002
Sci Rep. 2019 Oct 10;9(1):14567
pubmed: 31601959
Evid Based Ment Health. 2019 Nov;22(4):139-141
pubmed: 31511231
Age Ageing. 2016 Jul;45(4):535-42
pubmed: 27151390